• Level 3, 88 Jephson Street, Toowong, QLD 4066, Australia
  • +61 7 3331 3999

 Translational Research: An overnight success...10 years in the making

Translating medical research into clinical practice and commercial outcomes is not a pursuit for the faint hearted nor for those who are impatient! The road to outcomes takes a long time and with many hurdles to be overcome.

The QIMR Berghofer TRX16 conference aims to explore the journey by stimulating trans-disciplinary discussions and collaborations across areas of human disease research, drug and diagnostic discovery and development, IT and bioinformatics. 

QIMR Berghofer TRX16 will bring together key life sciences stakeholders from biopharmaceuticals, biotechnology, the R&D community, academia and government working to achieve enhanced research outcomes and value through the translation of data and knowledge into outcomes. 

The conference will provide an opportunity for stakeholders to interact with biopharmaceutical companies, technology companies and software providers; and catalyse possibilities to establish partnerships between these organisations from around the globe.

Announcements


  • REGISTRATIONS ARE NOW OPEN! CLICK HERE TO REGISTER TODAY!
  • Would you like to present at TRX16? Click here to learn how!
  • Want to be involved with more exposure? Click here to become a TRX16 Sponsor. 
  • We are pleased to announce that the QIMR Berghofer Translational Research Excellence 2016 (TRX16) Conference will be held at QIMR Berghofer Medical Research Institute on 21 October 2016.

Special thanks to our Sponsors and Supporters


TRX16 Hosts: 

         

 

    

              
                        
     Host Profile: 

QIMR Berghofer is a world-leading medical research institute, renowned for its efforts in both discovery research and translational research. The Institute’s research is focussed on cancer, infectious diseases, mental health, and chronic disorders.

Working in close collaboration with clinicians and research institutes, in Australia and around the world, the Institute’s aim is to improve health by developing prevention strategies, new diagnostics and better treatments.

QIMR Berghofer has invested in research and biotechnology facilities to help take discoveries through to clinical trials and into clinics. On site is a clinical trial facility, Q-Pharm, with expertise in first-time-in-human studies; and Q-Gen, approved to manufacture cellular therapies for human use, enabling clinical trials of new cancer treatments.

QIMR Berghofer is home to 55 research laboratory groups and around 900 scientists, students and support staff. Its location within the Herston Health Precinct, close to hospitals and university faculties and research centres, makes the Institute ideally placed for clinical research collaborations. QIMR Berghofer has an active program for the patenting and commercialisation of technologies, including those developed in conjunction with academic or commercial collaborators.
 
         
 TRX16 + GENE Sponsors: